Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003709 · ClinicalTrials.gov registry record · Phase 1

Chemotherapy in Treating Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target

NCT00003709: Completed Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.

NCT00003709 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003709, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced solid tumors.

Interventions

  • DRUG carbendazim

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 1998-10
Est. Completion 2000-11
Phase Phase 1

What the finished NCT00003709 record still lists

NCT00003709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 1 intervention - of which carbendazim is the first listed.

NCT00003709 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003709 about?

NCT00003709 is a clinical study titled "Chemotherapy in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced solid tumors.

What is the current status of trial NCT00003709?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1998-10. Estimated completion is 2000-11.

What interventions are being tested in trial NCT00003709?

The interventions under investigation include: carbendazim (DRUG).

Who is sponsoring clinical trial NCT00003709?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003709's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003709, the US trial registry maintained by the National Library of Medicine. NCT00003709 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.